European Archives - Page 940 of 1159 - European Medical Journal

Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management

Sickle cell disease is a genetic disorder caused by sickle haemoglobin. In many forms of the disease, the red blood cells can change shape upon…

Networking with Neurology Attending Congress: A First Timer’s Perspective

If you had asked me what the word congress meant to me a year ago, the connotations would have been extremely different to those which I picture today.

Link Established Between Iron Status and Coronary Artery Disease

IRON may have protective qualities against heart disease, suggests a new study examining iron levels in relation to coronary artery disease (CAD), by a…

3D-Printed Models: The Future of Heart Valve Replacement

OUTCOMES of heart valve replacements could be revolutionised through the use of three-dimensional (3D)-printed models, which could boost the success of…

EMJ

More Frequent Haemodialysis Improved Outcomes: The Wish Comes True at Home

This satellite symposium reviewed the challenges in providing dialysis to patients with kidney disease and outlined data supporting the effectiveness of…

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products…

Introducing EMJ Allergy & Immunology 2.1

United Kingdom, August 03, 2017: EMJ would like to welcome you to the latest edition of EMJ Allergy and Immunology. This much-anticipated eJournal…

EMJ Allergy & Immunology 2.1 2017

EMJ would like to welcome you to the latest edition of EMJ Allergy and Immunology. This much-anticipated eJournal contains a comprehensive summary…

Review of the 61st European Academy of Allergy and Clinical Immunology Congress 2017

The largest allergy congress in the world was this year hosted in the scenic city of Helsinki, Finland.

Rapid Desensitisation for the Management of Hypersensitivity Reaction to Biologicals: Infliximab and Adalimumab in Inflammatory Bowel Disease Patients

Biologicals in the treatment of inflammatory bowel disease are important, but their usefulness is limited in patients with hypersensitivity reaction.